Vitamin E protection against chemical-induced cell injury. II. Evidence for a threshold effect of cellular alpha-tocopherol in prevention of adriamycin toxicity.
The cardiomyopathy produced by the widely used anticancer drug adriamycin (ADR) is believed to be related to the production of reaction oxygen species and consumption of reduced glutathione (GSH) during redox cycling of the drug. Protection by vitamin E against the toxicity of ADR was studied in a model of compromised isolated hepatocytes, generated by physiological alterations in the concentration of cell calcium. A decrease in cell calcium concentration leads to a greater loss of endogenous alpha-tocopherol and enhances the intracellular hydrolysis of exogenous alpha-tocopheryl esters. With this model, vitamin E (alpha-tocopheryl succinate) at 25 microM protected the calcium-depleted hepatocytes against the toxicity of ADR, in association with greater cellular alpha-tocopherol content as compared to calcium-adequate cells. The incubation of calcium-adequate hepatocytes with increasing concentrations of alpha-tocopheryl succinate up to 200 microM demonstrated that maximal protection by vitamin E was directly dependent on the alpha-tocopherol content of the cells, regardless of the concentration of cell calcium. The viability of the cells was closely associated with the alpha-tocopherol-mediated maintenance of cellular protein thiols. Viability and protein thiol content of the cells were maximal at cellular alpha-tocopherol levels in the range 0.6-1.0 nmol/10(6) cells in both calcium-depleted and -adequate cells. It is suggested that the potential use of vitamin E as a protective agent against ADR toxicity in vivo be reevaluated with an emphasis placed on the threshold level of intracellular alpha-tocopherol in the critical target tissue.
D000818:Animals; D002118:Calcium / Q000502:physiology; D002330:Carmustine / Q000037:antagonists & inhibitors; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000037:antagonists & inhibitors* / Q000633:toxicity; D066298:In Vitro Techniques; D008054:Lipid Peroxides / Q000096:biosynthesis; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D011506:Proteins / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013438:Sulfhydryl Compounds / Q000378:metabolism; D014810:Vitamin E / Q000494:pharmacology* / Q000502:physiology
D008054:Lipid Peroxides; D011506:Proteins; D013438:Sulfhydryl Compounds; D014810:Vitamin E; D004317:Doxorubicin; D002118:Calcium; D002330:Carmustine